Published in J Biol Chem on March 18, 2002
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Retracted Novel management of oral cancer: a paradigm of predictive oncology. Clin Med Res (2004) 2.14
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem (2009) 1.53
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) (2013) 1.17
Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci U S A (2005) 1.17
The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3. Mol Cell Biol (2006) 1.16
Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol (2014) 1.15
Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. Mol Endocrinol (2008) 1.13
Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res (2009) 1.11
Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal (2007) 1.09
Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol (2004) 1.08
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control (2011) 1.06
Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A (2004) 1.04
COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer (2010) 0.99
NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res (2011) 0.99
NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis (2006) 0.99
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A (2010) 0.99
Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification. Carcinogenesis (2011) 0.98
Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem (2008) 0.97
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res (2013) 0.95
Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol (2008) 0.94
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res (2013) 0.92
Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol (2004) 0.92
Potential targets for colorectal cancer prevention. Int J Mol Sci (2013) 0.89
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) (2008) 0.87
Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory disease. Int J Mol Sci (2014) 0.85
COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer (2008) 0.85
Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2. Am J Pathol (2005) 0.85
The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem J (2005) 0.85
Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst (2008) 0.84
Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma. J Biol Chem (2009) 0.84
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
Clinical value of cyclooxygenase-2 expression in human breast carcinoma. Cancer Res Treat (2004) 0.83
The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n-3 PUFAs. Mol Nutr Food Res (2012) 0.82
Functional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women. Cancer Cell Int (2014) 0.82
The role of Pea3 group transcription factors in esophageal squamous cell carcinoma. Am J Pathol (2011) 0.81
Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis. PLoS One (2013) 0.81
Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects. Dis Markers (2014) 0.81
Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation. Oncotarget (2015) 0.81
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway. Onco Targets Ther (2016) 0.80
Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer. ScientificWorldJournal (2015) 0.80
Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors. Cancer Res Treat (2005) 0.80
1-{5-[4-(Hex-yloxy)phen-yl]-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl}ethanone. Acta Crystallogr Sect E Struct Rep Online (2010) 0.80
Study on cow ghee versus soybean oil on 7,12-dimethylbenz(a)-anthracene induced mammary carcinogenesis & expression of cyclooxygenase-2 & peroxisome proliferators activated receptor-γ in rats. Indian J Med Res (2011) 0.79
Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. Br J Cancer (2010) 0.79
Role of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer. Indian J Surg Oncol (2014) 0.79
Functional interaction of E1AF and Sp1 in glioma invasion. Mol Cell Biol (2007) 0.79
LKB1/PEA3/ΔNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxid Med Cell Longev (2010) 0.77
Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anticancer Agents Med Chem (2012) 0.77
Stromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients. BMC Cancer (2014) 0.76
4-[(5R*,10bR*)-2-Methyl-1,10b-dihydro-pyrazolo[1,5-c][1,3]benzoxazin-5-yl]benzoic acid. Acta Crystallogr Sect E Struct Rep Online (2008) 0.75
Role of traditional and new biomarkers in breast carcinogenesis. Ecancermedicalscience (2009) 0.75
Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. Breast Cancer (Auckl) (2009) 0.75
1-[5-(4-Meth-oxy-phen-yl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl]ethanone. Acta Crystallogr Sect E Struct Rep Online (2010) 0.75
2-Methyl-1,10b-dihydro-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-one. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75
The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer. Pharmaceuticals (Basel) (2010) 0.75
Role of Aspirin in Breast Cancer Survival. Curr Oncol Rep (2017) 0.75
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res (2009) 3.95
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer (2004) 3.03
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci (2003) 2.91
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest (2009) 2.55
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) (2010) 2.30
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol (2008) 2.28
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol (2007) 2.19
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer (2003) 2.06
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res (Phila) (2008) 2.04
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev (2011) 1.85
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol (2004) 1.82
Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol (2007) 1.79
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol (2008) 1.78
Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol (2007) 1.77
Clinical implications of cancer self-seeding. Nat Rev Clin Oncol (2011) 1.77
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol (2008) 1.75
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res (2006) 1.69
Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up. Am J Surg Pathol (2011) 1.68
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res (2010) 1.68
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) (2012) 1.66
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res (2008) 1.66
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol (2012) 1.62
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol (2009) 1.61
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev (2008) 1.61
Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem (2003) 1.60
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
ETS rearrangements and prostate cancer initiation. Nature (2009) 1.58
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer (2011) 1.56
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res (2005) 1.55
HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res (2006) 1.55
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genet (2008) 1.53
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol (2005) 1.51
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res (2012) 1.50
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res (2011) 1.47
Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) (2012) 1.44
Gene expression profiling in single cells within tissue. Nat Methods (2005) 1.43
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst (2003) 1.42
Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol (2007) 1.41
Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol (2010) 1.40
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal (2009) 1.39
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol (2010) 1.37